PE5596A1 - ANTIVIROSICO AGENT - Google Patents

ANTIVIROSICO AGENT

Info

Publication number
PE5596A1
PE5596A1 PE1994253128A PE25312894A PE5596A1 PE 5596 A1 PE5596 A1 PE 5596A1 PE 1994253128 A PE1994253128 A PE 1994253128A PE 25312894 A PE25312894 A PE 25312894A PE 5596 A1 PE5596 A1 PE 5596A1
Authority
PE
Peru
Prior art keywords
antivirosico
agent
flavine
virosic
schizoflavine
Prior art date
Application number
PE1994253128A
Other languages
Spanish (es)
Inventor
Washington Odur Ayuko
Original Assignee
Radopath Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Ltd filed Critical Radopath Ltd
Publication of PE5596A1 publication Critical patent/PE5596A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DE FLAVINA TAL COMO RIBOFLAVINA, LUMICROMO, ESQUIZOFLAVINA, FLAVINA ADENINA DINUCLEOTIDO, 8-HIDROXIFLAVINA, ALOXACINA Y OTROS; QUE ADMINISTRADO EN UNA DOSIS DE POR LO MENOS 10 mg/Kg DE PESO CORPORAL POR DIA, PODRIA SER UTIL EN EL TRATAMIENTO DE INFECCIONES VIROSICAS Y EN PARTICULAR DE HIVREFERS TO A COMPOUND DERIVED FROM FLAVINE SUCH AS RIBOFLAVINE, LUMICROME, SCHIZOFLAVINE, FLAVINE ADENINE DINUCLEOTIDE, 8-HYDROXIFLAVINE, ALOXACINE AND OTHERS; WHICH ADMINISTERED IN A DOSE OF AT LEAST 10 mg / Kg OF BODY WEIGHT PER DAY, COULD BE USEFUL IN THE TREATMENT OF VIROSIC INFECTIONS AND PARTICULAR HIV.

PE1994253128A 1993-10-19 1994-10-19 ANTIVIROSICO AGENT PE5596A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents

Publications (1)

Publication Number Publication Date
PE5596A1 true PE5596A1 (en) 1996-04-18

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1994253128A PE5596A1 (en) 1993-10-19 1994-10-19 ANTIVIROSICO AGENT

Country Status (26)

Country Link
EP (1) EP0739208A1 (en)
JP (1) JPH09505804A (en)
CN (1) CN1140992A (en)
AP (1) AP620A (en)
AU (1) AU7943794A (en)
BG (1) BG100599A (en)
BR (1) BR9407862A (en)
CA (2) CA2123825A1 (en)
CO (1) CO4520283A1 (en)
CZ (1) CZ113796A3 (en)
EE (1) EE9600057A (en)
GB (2) GB9321558D0 (en)
HR (1) HRP940688A2 (en)
HU (1) HUT76322A (en)
IL (1) IL111338A0 (en)
JO (1) JO1866B1 (en)
MA (1) MA23356A1 (en)
MD (1) MD960168A (en)
NO (1) NO961547L (en)
OA (1) OA10579A (en)
PE (1) PE5596A1 (en)
PL (1) PL314008A1 (en)
SK (1) SK50696A3 (en)
UY (1) UY23844A1 (en)
WO (1) WO1995011028A1 (en)
ZA (1) ZA948191B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (en) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd Interferon activity-enhancing agent and antivirus activity-enhancing composition containing the enhancing agent and interferon
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6933285B2 (en) * 2002-05-10 2005-08-23 The Ohio State University Flavin N-oxides: new anti-cancer agents and pathogen eradication agents
ITTO20020622A1 (en) 2002-07-16 2004-01-16 Dayco Europe Srl INTEGRATED PULLEY-TORSIONAL DAMPER GROUP
US20060293335A1 (en) * 2002-08-02 2006-12-28 Qishou Xu Riboflavin derivative and its manufacture and uses
EP2545788A1 (en) * 2011-07-13 2013-01-16 Martin Hulliger Dietary multi-component system
JP2018131410A (en) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 Caspase-3 inhibitor and use thereof
RU2020116649A (en) * 2017-10-24 2021-11-30 Лунелла Байотек, Инк. MITOFLAVOSCINS: Targeting Flavin-Containing Enzymes Eliminates Malignant stem cells (CSCS) by inhibiting mitochondrial respiration
CN114126603A (en) * 2019-07-09 2022-03-01 帝斯曼知识产权资产管理有限公司 Reduction of viral activity of elaverde with riboflavin or DHA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (en) * 1989-09-14 1998-03-11 三井農林株式会社 Influenza virus infection prevention agent
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (en) * 1991-04-02 1995-03-10 Jean Berque NEW THERAPEUTIC INDICATIONS, PARTICULARLY FOR THE TREATMENT OF AIDS, OF AN ALREADY EXISTING MEDICINAL PRODUCT FROM A DENIMOUS MOLECULE OF CONTRAINDICATIONS AND ADVERSE REACTIONS.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993010784A1 (en) * 1991-11-25 1993-06-10 University Of Michigan Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (en) * 1992-03-27 2000-08-07 雪印乳業株式会社 Sialic acid-bound 5-deazaflavin compounds

Also Published As

Publication number Publication date
HRP940688A2 (en) 1997-04-30
OA10579A (en) 2002-06-19
AP9400695A0 (en) 1995-01-31
ZA948191B (en) 1995-06-08
NO961547D0 (en) 1996-04-18
MD960168A (en) 1998-04-30
CO4520283A1 (en) 1997-10-15
AU7943794A (en) 1995-05-08
EE9600057A (en) 1996-10-15
BG100599A (en) 1997-02-28
CZ113796A3 (en) 1996-11-13
AP620A (en) 1997-10-14
IL111338A0 (en) 1994-12-29
HU9601006D0 (en) 1996-06-28
NO961547L (en) 1996-06-19
CA2174552A1 (en) 1995-04-27
HUT76322A (en) 1997-08-28
GB2283913A (en) 1995-05-24
CN1140992A (en) 1997-01-22
CA2123825A1 (en) 1995-04-20
JO1866B1 (en) 1995-12-27
EP0739208A1 (en) 1996-10-30
WO1995011028A1 (en) 1995-04-27
MA23356A1 (en) 1995-07-01
JPH09505804A (en) 1997-06-10
GB9321558D0 (en) 1993-12-08
UY23844A1 (en) 1995-03-28
PL314008A1 (en) 1996-08-05
SK50696A3 (en) 1997-01-08
BR9407862A (en) 1997-05-20
GB9421099D0 (en) 1994-12-07

Similar Documents

Publication Publication Date Title
PE5596A1 (en) ANTIVIROSICO AGENT
MY138860A (en) Hiv protease inhibitors.
ES2194902T3 (en) L-NUCLEOSIDS FOR THE TREATMENT OF THE HEPATITIS B VIRUS AND THE EPSTEIN BARR VIRUS.
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
CL2004002061A1 (en) COMPOUNDS DERIVED FROM CONDENSED HETEROCICLES CONTAINING NITROGEN; PHARMACEUTICAL COMPOSITION; AND ITS USE AS AN ANTIVIRAL AGENT, INTEGRASA INHUBIDATOR AND AS AN ANTI-HIV AGENT.
MD1434B2 (en) 1,3-Oxathiolan nucleoside analogues, pharmaceutical composition containing 1,3-oxathiolan nucleoside analogues and method of treatment of the viral infections
ES2157929T3 (en) BETA-D-DIOXOLANO-NUCLEOSIDOS ENANTIOMERAMENTLY PURE.
GEP20063799B (en) Tropane derivatives useful in therapy
BR9913932A (en) Use of glp-1 analogs in the treatment of stroke
ES2087061T3 (en) USE OF AIB RIBOSIDE OR RIBOTIDE FOR THE MANUFACTURE OF A MEDICATION AGAINST CARDIAC CRISIS OR MYOCARDIAL INFARCTION IN PATIENTS SUFFERING FROM Atherosclerosis.
AU4408597A (en) Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
BR9406893A (en) Use of ninth- and decapeptides for the preparation of a medicine to fight AIDS
ES2121000T3 (en) COMPOSITION USED AS THERAPEUTIC AGENT AGAINST CHRONIC VIRAL HEPATIC DISEASES.
ES2096455T3 (en) APPLICATION OF LAMOTRIGINE IN THE TREATMENT OF NEUROSIDA.
ES2063033T3 (en) USE OF IGF-II IN THE TREATMENT OF BONE DISEASES.
ES2174921T3 (en) HIV PROTEASE INHIBITORS.
BR9711647A (en) New derivatives of Dicafeoilquímica, their use, compositions with them and treatment methods using them.
AR022250A1 (en) PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B.
EP0695184A4 (en) Hiv protease inhibitors
ES2182847T3 (en) NUCLEOSIDS AND NUCLEOTIDES OF EXPANDED RING.
ES2105923B1 (en) COMPOSITIONS FOR THE TREATMENT OF AN INFECTION AND DISEASE CAUSED BY THE HEPATITIS B (HBV) VIRUS.
ES2189206T3 (en) BETA-ALCOXIACRYLATES AGAINST MALARIA.
MX9300205A (en) DISUBSTITUTED POLYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AU6870691A (en) Active agent against retrovirus group viruses, compositions containing same and their use

Legal Events

Date Code Title Description
FD Application declared void or lapsed